Tags

Type your tag names separated by a space and hit enter

Fingolimod therapy for multiple sclerosis.
Semin Neurol 2013; 33(1):37-44SN

Abstract

Because of its potent efficacy and oral route of administration, the approval of fingolimod as treatment for relapsing-remitting multiple sclerosis (MS) was highly anticipated. The therapeutic and adverse effects are mediated by modulation of sphingosine 1-phosphate receptors. Fingolimod inhibits the egress of lymphocytes from lymph nodes and may also have direct effects on the central nervous system. The clinical trials that led to the approval of fingolimod demonstrated benefit on relapses, disability progression, magnetic resonance imaging (MRI) activity, and brain volume loss in treatment-naïve and previously treated patients with relapsing-remitting MS. The use of fingolimod in clinical practice has been limited by concerns for cardiac effects, infection, and macular edema as well as the relative lack of long-term safety data for this drug with a novel mechanism of action. Additional clinical trial and postmarketing data suggest that fingolimod is a safe, effective, and well-tolerated treatment option when patients are selected and monitored appropriately.

Authors+Show Affiliations

Neurological Institute, The Mellen Center for Multiple Sclerosis Treatment and Research, Cleveland Clinic, Cleveland, OH 44195, USA. cohenj@ccf.orgNo affiliation info available

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't
Review

Language

eng

PubMed ID

23709211

Citation

Willis, Mary A., and Jeffrey A. Cohen. "Fingolimod Therapy for Multiple Sclerosis." Seminars in Neurology, vol. 33, no. 1, 2013, pp. 37-44.
Willis MA, Cohen JA. Fingolimod therapy for multiple sclerosis. Semin Neurol. 2013;33(1):37-44.
Willis, M. A., & Cohen, J. A. (2013). Fingolimod therapy for multiple sclerosis. Seminars in Neurology, 33(1), pp. 37-44. doi:10.1055/s-0033-1343794.
Willis MA, Cohen JA. Fingolimod Therapy for Multiple Sclerosis. Semin Neurol. 2013;33(1):37-44. PubMed PMID: 23709211.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Fingolimod therapy for multiple sclerosis. AU - Willis,Mary A, AU - Cohen,Jeffrey A, Y1 - 2013/05/25/ PY - 2013/5/28/entrez PY - 2013/5/28/pubmed PY - 2014/2/11/medline SP - 37 EP - 44 JF - Seminars in neurology JO - Semin Neurol VL - 33 IS - 1 N2 - Because of its potent efficacy and oral route of administration, the approval of fingolimod as treatment for relapsing-remitting multiple sclerosis (MS) was highly anticipated. The therapeutic and adverse effects are mediated by modulation of sphingosine 1-phosphate receptors. Fingolimod inhibits the egress of lymphocytes from lymph nodes and may also have direct effects on the central nervous system. The clinical trials that led to the approval of fingolimod demonstrated benefit on relapses, disability progression, magnetic resonance imaging (MRI) activity, and brain volume loss in treatment-naïve and previously treated patients with relapsing-remitting MS. The use of fingolimod in clinical practice has been limited by concerns for cardiac effects, infection, and macular edema as well as the relative lack of long-term safety data for this drug with a novel mechanism of action. Additional clinical trial and postmarketing data suggest that fingolimod is a safe, effective, and well-tolerated treatment option when patients are selected and monitored appropriately. SN - 1098-9021 UR - https://www.unboundmedicine.com/medline/citation/23709211/Fingolimod_therapy_for_multiple_sclerosis_ L2 - http://www.thieme-connect.com/DOI/DOI?10.1055/s-0033-1343794 DB - PRIME DP - Unbound Medicine ER -